Omeros Corporation (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages

Omeros Corporation (NASDAQ:OMER) has received a consensus recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $40.3333.

OMER has been the topic of several research reports. HC Wainwright upped their target price on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd.

Insider Activity at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Omeros by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after buying an additional 666,357 shares in the last quarter. UBS Group AG raised its holdings in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after acquiring an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC lifted its stake in Omeros by 6.3% in the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after purchasing an additional 95,979 shares in the last quarter. State Street Corp lifted its stake in Omeros by 26.9% in the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Up 0.2%

NASDAQ:OMER opened at $12.04 on Friday. The stock has a market capitalization of $853.64 million, a price-to-earnings ratio of -5.96 and a beta of 2.44. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The firm has a 50 day moving average of $12.38 and a 200 day moving average of $8.38.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.